Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2009 May 18;4(5):e5591. doi: 10.1371/journal.pone.0005591

The Association Risk of Male Subfertility and Testicular Cancer: A Systematic Review

Xiaoning Peng 1,*, Xiaomin Zeng 2, Sihua Peng 3, Defeng Deng 4, Jian Zhang 5,*
Editor: Roberta W Scherer6
PMCID: PMC2680046  PMID: 19440348

Abstract

Background

An association between male subfertility and an increased risk of testicular cancer has been proposed, but conflicting results of research on this topic have rendered this theory equivocal. To more precisely assess the association between subfertility and the risk of testicular cancer, we performed a systematic review of international epidemiologic evidence.

Principal Findings

We searched the Medline database for records from January 1966 to March 2008 complemented with manual searches of the literature and then identified studies that met our inclusion criteria. Study design, sample size, exposure to subfertility and risk estimates of testicular cancer incidence were abstracted. Summary relative risks (RRs) with 95% confidence intervals (CIs) were calculated using the DerSimonian and Laird model. All statistical tests were two-sided. We identified seven case-control studies and two cohort studies published between 1987 and 2005. Analysis of the seven case-control studies that included 4,954 participants revealed an overall statistically significant association between subfertility and increased risk of testicular cancer (summary RR = 1.68, 95% CI: 1.22 to 2.31), without heterogeneity between studies (Q = 8.46, P heterogeneity = 0.21, I 2 statistics = 0.29). The association between subfertility and testicular cancer was somewhat stronger in the United States (summary RR = 1.75, 95% CI: 1.01 to 3.02) than it was in Europe (summary RR = 1.53, 95% CI: 1.22 to 1.92). The source of the control subjects had a statistically significant effect on the magnitude of the association (population-based summary—RR = 2.15, 95% CI: 1.11 to 4.17; hospital-based summary—RR = 1.56, 95% CI: 0.93 to 2.61). After excluding possible cryptorchidism, an important confounding factor, we also found a positive association between subfertility and increased risk of testicular cancer (summary RR = 1.59, 95% CI: 1.28 to 1.98). These results were consistent between studies conducted in the United States and in Europe (Q = 0.20, P heterogeneity = 0.66). Of the two cohort studies that reported standardized incidence ratios, both reported a statistically significant positive association between subfertility and increased risk of testicular cancer.

Conclusions

Our findings support a relationship between subfertility and increased risk of testicular cancer and apply to the management of men with subfertility, and prevention and diagnosis of testicular cancer.

Introduction

Testicular cancer is uncommon in most countries with an incidence that ranges from ∼1/100,000 to 10/100,000 and accounts for ∼1% of all cancers in men but ∼60% of all cancers in young males 15–35 years of age. Moreover, the incidence of testicular cancer has doubled in the last 20–40 years [1], [2]. The most common type of testicular cancer is testicular germ cell tumor (TGCT) and accounts for 95% of testicular cancers.

TGCTs are presumed to arise from a common precursor lesion, carcinoma in situ (CIS), which is found within the seminiferous tubules. TGCTs comprise two histologically distinct subtypes: seminomas and non-seminomas. The seminoma subtype consists of cells that resemble CIS but that are not constrained within the seminiferous tubules. The non-seminoma subtype represents tumors of mixed histology, including embryonal carcinoma, teratoma, and polyembryoma, choriocarcinoma, or yolk sac tumor [3].

At present, the etiology of testicular cancer is not well understood, but many risk factors—including cryptorchidism (a condition in which one or both testes fail to descend normally); inguinal hernia; contralateral testicular cancer; familial testicular cancer; testicular trauma; mumps orchitis; elevated testicular temperature; vasectomy; electromagnetic fields (EMF); and hormonal, prenatal, and occupational factors—have been implicated in this cancer's development in young adults [4]. The nature of these factors suggests that both genetic and environmental influences contribute to the development of testicular tumors. Until now, the most established factor associated with testicular cancer is cryptorchidism, which is associated with a 2- to 4-fold increase in the risk of testicular cancer but accounts for fewer than 10% of all cases [5].

Over the last 20–40 years, reports in the literature indicate a decrease in the quality of sperm and an increase in the frequency of testicular malignancies (especially seminoma) [6][8]. As many as 10 to 15% of all couples in western countries experience subfertility (the condition of being less than normally fertile though still capable of effecting fertilization), and in one third of these cases, the problem can be attributed to the male partner [6][8]. An association between the world-wide decrease in male fertility and testicular cancer has been suggested [9][17], although evidence for this type of association has been inconsistent [18][21], and the exact etiology of such an association remains debatable.

The potential association between subfertility and the testicular cancer has evoked a huge interest from clinicians, scientists, and the public [22]. Thus, to elucidate and to provide a quantitative assessment of the association between male subfertility and testicular cancer, we performed a systematic review of studies that evaluated such an association and our results indicated that male subfertility is significantly related to an increased risk for testicular cancer.

Methods

Search strategy

We conducted a literature search of the Medline database (records from January 1, 1966, through March 31, 2008) using three search terms, which were combined by the Boolean operator “and.” The first theme was (“Testicular Neoplasms”[Mesh] OR “testicular cancer” OR “testicular tumour”), the second theme was (“Infertility”[Mesh] OR “Infertility, Male”[Mesh] OR “subfertility”), and the third theme was (“Case-Control Studies”[Mesh] OR “case–control study” OR “Cohort Studies”[Mesh] OR “cohort study”). We sought additional eligible studies by conducting a manual search of reference lists from primary articles and relevant reviews. We identified epidemiologic studies conducted in humans from 1966 to 2008 that examined the association between subfertility and testicular cancer incidence. Two readers independently determined the eligibility of each article for inclusion in the meta-analysis. Any disagreements during the selection process were resolved by discussion with a third author.

Selection

Eligible studies: 1) described a male population with an association between male subfertility and testicular cancer; 2) described a case-control study or cohort study; 3) for a case-control study, either provided an estimate of effect with odds ratio with 95% confidence interval (CI) or provided raw data from which and odds ratio that could be calculated; for a cohort study, provided an estimate of effect with rate ratio or standardized incidence ratio with 95% CI; 4) included a study population where the didagnosis of subfertility/fertility problem/infertility/low fertility prior to diagnosis of testicular cancer; and 5) were written in English.

Studies were excluded if no control group was included; if subjects had a history of cryptorchidism; if the indicators of male infertility, included offspring sex ratio, number of children, offspring twin rates, and offspring sibship size.These indicators are imperfect measures of male fertility, as they depend not the combined reproductive capacity of both the male and female partner. If duplicate publications from a single study were found,then we included only the article that provided more comprehensive information and was written in English.

Validity assessment

Case-control studies were evaluated for quality using the quality assessment scale developed by Horwitz RI and colleagues [23], which include12 methodologic standards. For each study, compliance with each developed recommendation was rated according to the following possible scores: positive (+), negative (−), uncertain (±), and not applicable (NA) or not evaluable (NE). For cohort studies, we recorded the following quality indicators: approach to participant recruitment, length of follow-up, and consideration of confounding factors.

Data abstraction

For each study, we abstracted the following data: 1) first author's name, year of publication, and country of the population studied; 2) study design; 3) characteristics of the study subjects (source of cases and controls, follow-up period for cohort studies); 4) number of exposed and unexposed subjects; 5) measures of outcome and exposure; 6) variables for which statistical adjustment was performed; 7) the relative risk (RR) or relative odds of testicular cancer being associated with subfertility and its 95% CI; and 8) history of cryptorchidism.

Quantitative data synthesis

RR was used as the measure of effect of interest. We used the DerSimonian and Laird random-effects model to calculate a pooled RR and its corresponding 95% CI for studies that reported specific RRs [24], [25]. RRs from individual studies were transformed to their logarithms to stabilize the variances and to normalize the distributions. To assess for heterogeneity of RRs across studies, the Cochrane Q's statistic and the Inline graphic statistic were calculated [26]. The variance of the Inline graphic was derived from the CI provided in the study [27].

Sensitivity analyses were performed by omitting one study at a time and analyzing the remaining studies to detect whether the results were influenced excessively by any single study. The possibility of publication bias was assessed using visual inspection of a funnel plot [28], and both the Begg and Egger tests were also performed to assess the possibility of publication bias [29]. Furthermore, the Duval and Tweedie nonparametric trim-and-fill procedure was performed to further assess the possible effect of publication bias in our meta-analysis [30]. This method considers the possibility of hypothetical “missing” studies that might exist, imputes their RRs, and recalculates a pooled RR that incorporates the hypothetical missing studies as though they actually existed. Meta-analysis was performed using Microsoft Excel (Microsoft Corp, Seattle, Washington), SPSS11.5 (SPSS Corp, Chicago, Illinois), and Stata version 10.0 (Stata Corp, College Station, Texas). P values less than 0.05 were considered statistically significant, and all statistical tests were two-sided.

Results

Flow of included studies

From our review of abstracts, we initially selected 139 studies for a more detailed review (References S1); we excluded 126 studies because they were reviews, studies of other risk factors, or case reports. From the remaining 13 studies, we excluded four because the indicator to measure the male fertility problem was one of the following: sex ratio, twin rates, and sibship size of offspring—or because the population diagnosed with subfertility had a history of cryptorchidism (Table 1). After review, nine studies were included in the meta-analysis. Of the nine studies, seven were case-control studies—four from the United States and three from Europe; two of the nine were cohort studies—one from the United States and one from Europe (Fig. 1).

Table 1. Reasons for four studies excluded from the meta-analysis.

First author Year (Ref. No.) Region Design Reasons for Exclusion
Richiardi L 2004 (15) Europe Cohort Included participants with a history of cryptorchidism; used offspring twinning rates to define infertility
Fossa SD 2000 (16) Europe Cohort Used number of children to define infertility
Jacobsen R 2000 (17) Europe Cohort Used offspring sex-ratio to define infertility
Henderson BE 1979 (21) USA Case-control Used offspring sibship size to define infertility

Figure 1. QUOROM flow diagram (flow of included studies).

Figure 1

Study characteristics

The characteristics of the included studies are listed in Table 2 (for case-control studies) and Table 3 (for cohort studies). The nine studies that we included in the meta-analysis were published between 1987 and 2005. The studies about subfertility were registries or interviews and questionnaires. Seven case-control studies used odds ratios and the 95% CIs as the measure of RR [9][12], [18][20] and enrolled a total of 4,954 participants. The total subfertility case number was 2,099 (range of case subjects: 140 to 514), and the total number of control subjects was 2,855 (range of control subjects: 135 to 720). Case subjects were all identified in the cancer registry, with three hospital-based control subjects [12], [18], [20] and four population-based control subjects [9][11], [19]. Two cohort studies used standardized incidence ratios and the 95% CIs as the measure of RR [13], [14] and had enrolled a total of 36,289 participants, with a mean follow-up period ranging from 6 to 20 years. Five studies were conducted in the United States (four case-control studies and one cohort study) and four in Europe (three case-control studies and one cohort study).

Table 2. Characteristics of seven case-control studies of subfertility and testicular cancer incidence.

First Author Year (Ref. No.) Country Excluded Cryptorchidism No. of Cases (Source of Cases)/No. of Controls (Selection Method) Estimated Odds Ratios (95% CI) Controlled Variables
Baker JA 2005 (9) USA NA* 201 (Cancer registry)/204 (Population controls matched by age and area of residence) 9.47 (1.19–75.2) Age, neighborhood
Møller H 1999 (10) Europe (Danish) Yes 514 (Cancer registry)/720 (Population controls matched by age) 1.42 (1.09–1.85) Age
Doria-Rose VP 2005 (11) USA Yes 329 (Cancer registry)/672 (Population controls matched by age, race, language and area of residence) 2.51 (1.07–5.86) Age
Swerdlow AJ 1989 (12) Europe (England) Yes 178 (Cancer registry)/315 (Hospital patients matched by treatment center, area of residence and duration of follow-up) 1.73 (1.09–2.74) Area of hospital
Forman D PM 1994 (18) Europe (England and Wales) Yes 775 (Cancer registry)/794 (Hospital patients matched by age, register hospital or center, enrollment date and area of residence) 2.66 (0.94–7.54) Age, area of residence, and register-time
Haughey BP 1989 (19) USA Yes 250 (Cancer registry)/250 (Population controls matched by age and neighborhood of residence) 4.77 (0.40–52.50) Age, neighborhood
Brown LM 1987 (20) USA NA 140 (Cancer registry)/135 (Hospital patients without cancer matched by treatment hospital, age, race, vital status, year of diagnosis, and hospital of diagnosis) 0.89 (0.40–1.96) Age, race, vital status and year of diagnosis
*

NA, not available. CI, confidence interval.

Table 3. Characteristics of two cohort studies of subfertility and testicular cancer incidence.

First author Year (Ref. No) Country Excluded Cryptorchidism Study Population Follow-up Period Estimated Standardized Incidence Ratios (95% CI) Controlled Variables
Jacobsen R 2000 (13) Europe (Danish) NA* Exposed group: 32,442 subjects with a semen analysis (No. of cases: 89) 1963–1995 1.60 (1.30–1.90) Age
Comparison group: Danish population
Raman JD 2005 (14) USA Yes Exposed group: 3,847 subjects with abnormal semen analysis (No. of cases: 8) 1990–2000 18.30 (18.00–18.80) Age, race
Comparison group: American population
*

NA, not available.

Quality assessment

The quality assessment score for the included seven case-control studies is presented in Table 4. The criteria “Predetermined method of selection”, “Specification of the causal agent”, “Avoidance of constrained cases”, and “Avoidance of constrained controls” were scored as positive in all studies. “Unbiased data collection” was scored as positive in one study [12], negative in one study [10], and uncertain in four studies [9], [19]. “Anamnestic equivalence” was scored as positive in two studies [9], [12], and “Equal demographic susceptibility” was scored as positive in six studies and uncertain in one study [9], [19]. “Equal clinical susceptibility” was scored as positive in five studies and NA/NE in two studies [9], [19]. “Avoidance of Berkson's bias” was scored as positive in four studies [9], [19] and negative in three studies [9], [19]. “Equal diagnostic examination” was scored as positive in two studies [9], [19] and NA/NE in five studies. Table 5 presents corresponding quality criteria for the two cohort studies that were included in our review, and these two studies met many of the measured quality criteria [9], [19].

Table 4. Compliance with the 12 methodologic criteria in seven case-control studies.

First Author Baker JA Møller H Doria-Rose VP Swerdlow AJ Forman D PM Haughey BP Brown LM
Year (Ref. No.) 2005 (9) 1999 (10) 2005 (11) 1989 (12) 1994 (18) 1989 (19) 1987 (20)
Predetermined method + + + + + + +
Specification of the agent + + + + + + +
Unbiased data collection ± ± + ± ±
Anamnestic eauivalence + ± + ± ± ±
Avoidance of constrained cases + + + + + + +
Avoidance of constrained controls + + + + + + +
Equal diagnostic examination + +
Equal diagnostic surveillance
Equal demographic susceptibility + + + ± + + +
Equal clinical susceptibility + + + + +
Avoidance of protopathic bias
Community control for Berkson's bias + + + +

+, positive; −, negative; ±, uncertain; △, not applicable or not evaluable.

Table 5. Quality indicators for cohort studies.

First author Year (Ref. No) Same mode of inclusion for intervention and control group Enough F/U duration Report of loss of F/U Adjusted analysis for confounding variables Mode of participants selection described Potential important baseline differences Sample size prespecified Report of important baseline characteristics modification during F/U
Jacobsen R 2000 (13) Yes Yes No Yes Yes No Yes No
Raman JD 2005 (14) Yes Yes No Yes Yes Yes Yes Yes

Quantitative data synthesis

Individual study results and the overall summary results for the seven case-controlled studies on the association between subfertility and testicular cancer incidence are shown in Table 6. By pooling the results of these seven studies [9][12], [18][20], we found that subfertility was associated with an increased risk of testicular cancer (summary RR = 1.68, 95% CI: 1.22 to 2.31)(Fig. 2). In a sensitivity analysis in which one study at a time was excluded and the rest were analyzed, we detected a statistically significant positive association between subfertility and testicular cancer incidence (range of summary RRs = 1.56 to 1.92 and all the lower limit of the 95% CIs>1.0).We then conducted subgroup meta-analyses by the source of control subjects, geographical area, and possible presence of cryptorchidism. Analysis of four studies that included population-based control subjects showed a positive association (summary RR = 2.15, 95% CI = 1.11 to 4.17). Analysis of three studies with hospital-based subjects [12], [18], [20], did not support an association between subfertility and higher incidence of testicular cancer (summary RR = 1.56, 95% CI = 0.93 to 2.61).

Table 6. Summary relative risk (RR) estimates and 95% confidence intervals (CIs) for seven case-control studies of the association between subfertility and testicular cancer incidence.

Subgroup Studies (No.) Summary RR (95% CI) Between Studies
Q P Heterogeneity I 2 Statistics
Case-control studies 7 1.68 (1.22 to 2.3) 8.46 0.21 0.29
Population-based 4 2.15 (1.11 to 4.17) 5.36 0.15 0.44
Hospital-based 3 1.56 (0.93 to 2.61) 3.09 0.21 0.35
Region 0.20* 0.66
United States 4 1.75 (1.01 to 3.02) 6.61 0.09 0.55
Europe 3 1.53 (1.22 to 1.92) 1.66 0.44 0.20
Excluded cryptorchidism 5 1.59 (1.28 to 1.98) 3.63 0.46 0.10
*

for between subgroup.

Figure 2. Association between subfertility and testicular cancer incidence in the seven case-control studies.

Figure 2

We found that a positive association between subfertility and testicular cancer by region (the United States and Europe), with a somewhat stronger association in the United States [9], [11], [19][20] (summary RR = 1.75, 95% CI = 1.01 to 3.02) than in Europe [10], [12], [18] (summary RR = 1.53, 95% CI = 1.22 to 1.92).

As a strong risk factor for both testicular cancer and subfertility, cryptorchidism is a potentially important confounder of the positive association between subfertility and testicular cancer. We analyzed five studies [10][12], [18][19] that excluded participants with a history of cryptorchidism, and found a positive association between subfertility and testicular cancer (summary RR = 1.59, 95% CI = 1.28 to 1.98).

Both cohort studies identified (one conducted in the United States and the other in Europe) [13], [14] reported a standardized incidence ratios and a statistically significant positive association between subfertility and testicular cancer (United States population RR = 18.3, 95% CI = 18.0 to 18.8; Danish population RR = 1.6, 95% CI = 1.3 to 1.9).

Publication bias

The funnel plot appears asymmetric (Fig. 3A), suggesting publication bias—although the Begg test and Egger test were not statistically significant (P = 0.23 and 0.11, respectively). Therefore, we performed a sensitivity analysis by using the trim-and-fill method [30], which conservatively imputes hypothetical negative unpublished studies to mirror the positive studies that cause funnel plot asymmetry. The imputed studies produce a symmetrical funnel plot (Figure 3B). The pooled analysis incorporating the hypothetical studies continued to show a statistically significant association between testicular cancer and subfertility (with adjusted RR = 1.51, 95% CI: 1.08–2.12; P<0.017).

Figure 3. Funnel plots with and without trim and fill.

Figure 3

Discussion

Discrepancies among previous studies investigating the relationship of subfertility with testicular cancer risk may be attributable to small sample sizes that resulted in insufficient statistical power to detect some relationships in the individual studies. To address this uncertainty, we used rigorous meta-analytic techniques to quantitatively assess the association more precisely. The results of our meta-analysis support the association of subfertility with subsequent risk for testicular cancer.

By pooling data from seven case-control studies meeting our inclusion criteria, we demonstrated that individuals with subfertility have an overall increased RR of developing testicular cancer compared with control individuals; the results suggested a consistent positive association between subfertility and testicular cancer for studies carried out in the United States and in Europe, for studies of population-based and hospital-based control subjects, and for studies that completely excluded cryptorchidism. Two cohort studies could not be made into a pooled analysis because standardized incidence ratios were used as the measure of effect of interest; however, both studies reported a statistically significant positive association between subfertility and testicular cancer, with a 1.6-and an 18.3-fold increased risk of testicular cancer among subfertility patients, respectively.

Like all meta-analyses, this study had some limitations. First, the definition of subfertility in this systematic review is a somewhat comprehensive definition, and we included the studies that reported on men who had been diagnosed with subfertility/fertility problem/infertility/low fertility due to difficulty getting a partner pregnant or to a sperm problem prior to a diagnosis of testicular cancer. Second, the quality of case-control individual studies was inconsistent as is shown in Table 4, with a lack of unbiased data collection, anamnestic equivalence, equal diagnostic examination, equal clinical susceptibility, and “community control” for Berkson's bias for some studies. Third, we only found two cohort studies that reported standardized incidence ratios and satisfied our inclusion criteria, and the data from these two cohort studies could not be pooled with data from case-control studies. In addition, we only found five studies that reported no history of cryptorchidism and restricted our search strategy to include articles in English only.

The results we obtained from the funnel plot analysis were consistent with publication bias, that is, the presence of unpublished negative studies. Because of this, we undertook a sensitivity analysis using the trim-and-fill method. The trim-and-fill sensitivity analysis did not change direction of the results, although the strength of the association was somewhat weakened, indicating that the association is not an artifact of unpublished negative studies. Nevertheless, that possibility is not fully excluded by this method. Therefore, further studies are needed to supplement the results of this meta-analysis.

A relationship between subfertility and increased risk of testicular cancer is epidemiologically plausible. First, it has been suggested that during the past four decades human sperm counts have declined and the incidence of testicular cancer has increased [31][33]. Second, the incidence rate of testicular cancer in infertile men (∼0.5–1%) is much higher than that of the general population (0.001%∼0.01%), and men who present with subfertility are of a similar age as men with the highest prevalence of testicular cancer [14], [34], [35]. Third, after excluding the common risk factors for testicular cancer and subfertility, such as the history of cryptorchidism and chromosomal aberrations, men with infertility also have an increased risk of developing testicular cancer [11], [14], [22].

A relationship between subfertility and increased risk of testicular cancer is biologically plausible. First, fetal and neonatal life are important in the development of reproductive disorders, and some studies have shown that in utero exposure to excess environmental estrogens (EES) is a risk factor for subfertility and testicular cancer [15], [36][38]. Though the mechanism that mediates these effects is not well understood, some investigators propose that EES not only interferes in the normal testis endocrine directly but also disrupts the hypothalamic-pituitary-testis axis, resulting in abnormal function of sertoli cells; this disruption impairs germ cell differentiation and the germ cells are subsequently transformed to develop into carcinoma in situ (CIS) [4], [39]. Estimates predict that CIS will develop into testicular cancer within 5 years of diagnosis in half of all cases, and all patients who harbor CIS cells at puberty will eventually develop testicular cancer [4].

Second, genetic defects provide robust evidence in favor of a relationship between subfertility and increased risk of testicular cancer. Brothers of men with testicular cancer have lower fertility and a higher risk of having testicular cancer than age matched controls [16]. The “gr/gr” (carries a number of genes specifically involved in male germ cell development) deletion in the Y chromosome has been found to be associated with subfertility and TGCT [40]. Youngren et al. found that the Ter mutation in the dead end gene (Dnd1) causes primordial germ cell (PGCs) loss and TGCTs, and loss of PGCs precedes development of embryonal carcinoma cells in 129-Ter/Ter mouse embryos [41]. Therefore, inactivation of Dnd1 expression is implicated as the causal event that drives PGCs to exit the germ line and transform to embryonal carcinoma cells and TGCTs in 129-Ter/Ter mice [41].

Our findings provide evidence for a role of subfertility in carcinogenesis of testicular cancer. Our study numbers were limited and all of the involved studies were conducted in the United States and Europ. In addition, selection and recall biases may affect the association between male subfertility and the subsequent development of testicular cancer. More and larger case control studies or prospective studies with multi-regional and multi-institutional cohorts of men presenting for subfertility or infertility care are needed for a clearer determination of the association of subfertility with increased risk of testicular cancer.

Testicular cancer has a complex etiology; environmental factors and genetic mutations both contribute to the increased risk of developing testicular cancer. Therefore, future studies will take up the exciting challenge to elucidate the mechanism of the interaction between environmental factors and genetic mutations (such as how the estrogen regulates the related gene of germ cell development) that influences the spermatogenesis and carcinogenesis of germ cells.

Supporting Information

References S1

(0.07 MB DOC)

Acknowledgments

We would like to acknowledge Kristi M. Speights for excellent editorial assistance and insightful suggestions.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This project was supported by NSFH (Natural Science foundation of Hunan) grants (No. 07JJ6059) to Xiaoning Peng and with Talent Young Scientists Fund of Hunan Normal University to Xiaoning Peng (No. 070626). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. The Journal of urology. 2003;170:5–11. doi: 10.1097/01.ju.0000053866.68623.da. [DOI] [PubMed] [Google Scholar]
  • 2.Walschaerts M, Huyghe E, Muller A, Bachaud J-M, Bujan L, et al. Doubling of testicular cancer incidence rate over the last 20 years in southern France. Cancer causes & control : CCC. 2008;19:155–161. doi: 10.1007/s10552-007-9081-x. [DOI] [PubMed] [Google Scholar]
  • 3.Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO. 2005;16:863–868. doi: 10.1093/annonc/mdi175. [DOI] [PubMed] [Google Scholar]
  • 4.Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: an overview. International journal of cancer Journal international du cancer. 2005;116:331–339. doi: 10.1002/ijc.21032. [DOI] [PubMed] [Google Scholar]
  • 5.Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World journal of urology. 2004;22:2–14. doi: 10.1007/s00345-004-0398-8. [DOI] [PubMed] [Google Scholar]
  • 6.Snick HK, Snick TS, Evers JL, Collins JA. The spontaneous pregnancy prognosis in untreated subfertile couples: the Walcheren primary care study. Human reproduction (Oxford, England) 1997;12:1582–1588. doi: 10.1093/humrep/12.7.1582. [DOI] [PubMed] [Google Scholar]
  • 7.Evers JLH. Female subfertility. Lancet. 2002;360:151–159. doi: 10.1016/S0140-6736(02)09417-5. [DOI] [PubMed] [Google Scholar]
  • 8.Chow V, Cheung AP. Male infertility. The Journal of reproductive medicine. 2006;51:149–156. [PubMed] [Google Scholar]
  • 9.Baker JA, Buck GM, Vena JE, Moysich KB. Fertility patterns prior to testicular cancer diagnosis. Cancer causes & control : CCC. 2005;16:295–299. doi: 10.1007/s10552-004-4024-2. [DOI] [PubMed] [Google Scholar]
  • 10.Moller H, Skakkebaek NE. Risk of testicular cancer in subfertile men: case-control study. BMJ (Clinical research ed ) 1999;318:559–562. doi: 10.1136/bmj.318.7183.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Doria-Rose VP, Biggs ML, Weiss NS. Subfertility and the risk of testicular germ cell tumors (United States). Cancer causes & control : CCC. 2005;16:651–656. doi: 10.1007/s10552-005-0169-x. [DOI] [PubMed] [Google Scholar]
  • 12.Swerdlow AJ, Huttly SR, Smith PG. Testis cancer: post-natal hormonal factors, sexual behaviour and fertility. International journal of cancer Journal international du cancer. 1989;43:549–553. doi: 10.1002/ijc.2910430403. [DOI] [PubMed] [Google Scholar]
  • 13.Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ (Clinical research ed) 2000;321:789–792. doi: 10.1136/bmj.321.7264.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. The Journal of urology. 2005;174:1819–1822; discussion 1822. doi: 10.1097/01.ju.0000177491.98461.aa. [DOI] [PubMed] [Google Scholar]
  • 15.Richiardi L, Akre O, Montgomery SM, Lambe M, Kvist U, et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. Journal of the National Cancer Institute. 2004;96:145–147. doi: 10.1093/jnci/djh012. [DOI] [PubMed] [Google Scholar]
  • 16.Fossa SD, Kravdal O. Fertility in Norwegian testicular cancer patients. British journal of cancer. 2000;82:737–741. doi: 10.1054/bjoc.1999.0989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jacobsen R, Bostofte E, Engholm G, Hansen J, Skakkebaek NE, et al. Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study. Human reproduction (Oxford, England) 2000;15:1958–1961. doi: 10.1093/humrep/15.9.1958. [DOI] [PubMed] [Google Scholar]
  • 18.Forman D PM, Davey G, et al. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. United Kingdom Testicular Cancer Study Group. BMJ (Clinical research ed) 1994;308:1393–1399. [PMC free article] [PubMed] [Google Scholar]
  • 19.Haughey BP, Graham S, Brasure J, Zielezny M, Sufrin G, et al. The epidemiology of testicular cancer in upstate New York. American journal of epidemiology. 1989;130:25–36. doi: 10.1093/oxfordjournals.aje.a115319. [DOI] [PubMed] [Google Scholar]
  • 20.Brown LM, Pottern LM, Hoover RN. Testicular cancer in young men: the search for causes of the epidemic increase in the United States. Journal of epidemiology and community health. 1987;41:349–354. doi: 10.1136/jech.41.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Henderson BE, Benton B, Jing J, Yu MC, Pike MC. Risk factors for cancer of the testis in young men. International journal of cancer Journal international du cancer. 1979;23:598–602. doi: 10.1002/ijc.2910230503. [DOI] [PubMed] [Google Scholar]
  • 22.de Kretser D. Testicular cancer and infertility. BMJ (Clinical research ed) 2000;321:781–782. doi: 10.1136/bmj.321.7264.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Horwitz RI, Feinstein AR. Methodologic Standards and Contradictory Results in Case-Control Research. American Journal of Medicine. 1979;66:556–564. doi: 10.1016/0002-9343(79)91164-1. [DOI] [PubMed] [Google Scholar]
  • 24.Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiologic reviews. 1987;9:1–30. doi: 10.1093/oxfordjournals.epirev.a036298. [DOI] [PubMed] [Google Scholar]
  • 25.DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 26.Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. doi: 10.1002/sim.1186. [DOI] [PubMed] [Google Scholar]
  • 27.Kahn HA, Sempos C. Statistical methods in epidemiology. Vol. 12 of Epidemiology and biostatistics. New York: Oxford University; 1989. [Google Scholar]
  • 28.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Begg CB, Mazumdar M. Operating Characteristics of a Bank Correlation Test for Publication Bias. Biometrics. 1994;50:1088–1101. [PubMed] [Google Scholar]
  • 30.Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463. doi: 10.1111/j.0006-341x.2000.00455.x. [DOI] [PubMed] [Google Scholar]
  • 31.Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P, et al. Male reproductive health and environmental xenoestrogens. Environmental health perspectives. 1996;104(Suppl 4):741–803. doi: 10.1289/ehp.96104s4741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Skakkebaek NE, Jorgensen N, Main KM, Rajpert-De Meyts E, Leffers H, et al. Is human fecundity declining? International journal of andrology. 2006;29:2–11. doi: 10.1111/j.1365-2605.2005.00573.x. [DOI] [PubMed] [Google Scholar]
  • 33.Giwercman A, Rylander L, Lundberg Giwercman Y. Influence of endocrine disruptors on human male fertility. Reproductive biomedicine online. 2007;15:633–642. doi: 10.1016/s1472-6483(10)60530-5. [DOI] [PubMed] [Google Scholar]
  • 34.Mancini M, Carmignani L, Gazzano G, Sagone P, Gadda F, et al. High prevalence of testicular cancer in azoospermic men without spermatogenesis. Human reproduction (Oxford, England) 2007;22:1042–1046. doi: 10.1093/humrep/del500. [DOI] [PubMed] [Google Scholar]
  • 35.Olesen IA, Hoei-Hansen CE, Skakkebaek NE, Petersen JH, Rajpert-De Meyts E, et al. Testicular carcinoma in situ in subfertile Danish men. International journal of andrology. 2007;30:406–411; discussion 412. doi: 10.1111/j.1365-2605.2007.00798.x. [DOI] [PubMed] [Google Scholar]
  • 36.Weir HK, Marrett LD, Kreiger N, Darlington GA, Sugar L. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. International journal of cancer Journal international du cancer. 2000;87:438–443. doi: 10.1002/1097-0215(20000801)87:3<438::aid-ijc20>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  • 37.Depue RH, Pike MC, Henderson BE. Estrogen exposure during gestation and risk of testicular cancer. Journal of the National Cancer Institute. 1983;71:1151–1155. [PubMed] [Google Scholar]
  • 38.Heimdal K, Olsson H, Tretli S, Flodgren P, Borresen AL, et al. Risk of cancer in relatives of testicular cancer patients. British journal of cancer. 1996;73:970–973. doi: 10.1038/bjc.1996.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. Nature reviews Cancer. 2005;5:210–222. doi: 10.1038/nrc1568. [DOI] [PubMed] [Google Scholar]
  • 40.Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. American journal of human genetics. 2005;77:1034–1043. doi: 10.1086/498455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Youngren KK, Coveney D, Peng XN, Bhattacharya C, Schmidt LS, et al. The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature. 2005;435:360–364. doi: 10.1038/nature03595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

References S1

(0.07 MB DOC)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES